Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate.
Thirty-eight patients with cancer of the prostate were treated with strict parenteral estrogen in the form of monthly polyestradiol phosphate injections--160 mg, 240 mg, and 320 mg--in this nonrandomized study. In contrast to studies with oral estrogens, there have been no cardiovascular complications at a mean follow-up of 12.9 +/- 0.7 months (SEM). Twenty-nine of the 38 patients (76%) have responded to therapy.
Henriksson
P
P
Department of Medicine, Huddinge University Hospital, Sweden.
Eriksson
A
A
Stege
R
R
Collste
L
L
Pousette
A
A
von Schoultz
B
B
Carlström
K
K
D000368:Aged; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000453:epidemiology; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D045166:Estradiol Congeners / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012307:Risk Factors
D045166:Estradiol Congeners; D004958:Estradiol; C008958:polyestradiol phosphate